



Press release from Emotra AB (publ)

Göteborg, November 20, 2020

## Notice of extraordinary general meeting of shareholders in Emotra AB (publ)

**Notice is hereby given that an extraordinary general meeting of shareholders in Emotra AB (publ), 556612-1579, will be held at 11 am on Friday December 4, in the conference room Saltö at Folkets Hus, 3 Olof Palmes Plats, 413 04 Göteborg, Sweden.**

### **Right of Participation and Registration**

Shareholders who wish to participate in the meeting must

- be registered in the share register maintained by Euroclear Sweden AB by Thursday November 26, 2020 and
- send a written notice to the Company of their intent to participate in the meeting. The notice must arrive at the Company no later than Tuesday December 1, 2020 at the address Emotra AB, AstraZeneca BioVentureHub, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.

Shareholders may also register their intent to participate directly to our CEO, Daniel Poté, by calling +46 732 34 91, or by sending an e-mail to [daniel@emotra.se](mailto:daniel@emotra.se).

The registration notice must contain the shareholder's full name, personal or corporate ID number, number of shares in possession, address, daytime telephone number and, where appropriate, information about any deputies or counsel (2 at the most). Where appropriate, the registration notice must be accompanied by proxy letters, certificates of registration as well as other necessary credentials.

As a precautionary measure due to the continued spread of the Corona virus, we will not be offering any refreshments or opportunity to mingle in connection with the shareholder meeting. Any shareholder who shows the slightest symptoms of illness, who has a family member who is sick, who has been abroad in the two-week period prior to the meeting, or who belongs to a risk group, is advised not to participate in this meeting. Instead, we advise you to vote by proxy. The above restrictions also apply to any legal/financial counsel. The Company's ambition at the time of publication of the summons, is to make this extraordinary meeting as short and efficient as possible.

### **Nominee-registered shares**

To be eligible to participate in this meeting, any non-registered shareholder whose shares are registered in the name of a trustee, bank or other custodian must temporarily transfer registration of these shares to their own name in the ledger maintained by Euroclear Sweden AB. This transfer of registered ownership must be completed by Thursday November 26, 2020, which means that shareholders who wish to carry out such a transfer must inform their trustee well in advance of this date.

**Proxy, etc.**



If a shareholder wishes to be represented by a proxy, this proxy must present a written and dated proxy letter, signed by the shareholder, at the meeting. The proxy letter may not be more than one year old, unless the proxy letter states a longer duration (however, limited to five years). If the proxy letter has been issued by a legal entity, the proxy must also present a current certificate of registration or equivalent letter of authorisation for this legal entity. In order to facilitate admittance to the meeting, a copy of the proxy letter and any other letters of authorisation should be appended to the participation registration notice. Proxy forms are available on the Company's web site, [www.emotra.se](http://www.emotra.se), and can also be sent on request to shareholders who contact the Company and provide their address.

### **Number of Shares and Votes**

At the moment of publication of this notice, there are 47,659,009 shares outstanding and votes in the Company. The Company does not possess any own shares.

### **Suggested Agenda:**

0. Opening of the meeting.
1. Election of a chairperson for the meeting.
2. Establishing a voting list.
3. Approval of the meeting agenda.
4. Election of one or two persons to verify the minutes.
5. Approval that notice of the meeting was duly served.
6. Election of auditor or auditing company and any deputy auditor.
7. Resolution authorising the Board to issue new shares.
8. Other business.
9. Close of meeting.

### Summary of the proposals:

#### **Election of auditor (item 6)**

The proposal to the meeting is to elect the certified public accountant Lars Magnus Frisk of Guide Revision AB as the Company's auditor. The proposal to the meeting is to elect the certified public accountant Carina Fridberg, Guide Revision AB as the Company's deputy auditor.

#### **Resolution authorising the Board to issue new shares (item 7)**

The Board proposes that the extraordinary general meeting resolves to authorise the Board to issue new shares, within the framework of the present articles of association, on one or more occasions up until the next AGM, with or without deviation from the shareholders' right of priority.

The number of shares issued under the authorisation shall correspond to a maximum amount of 15 MSEK (total issue proceeds).

The shares will be issued at a market-equivalent price, minus a market-rate issue rebate, when appropriate, and payment can, in addition to cash, be made in kind or as otherwise conditioned.

The goal of any new share issue that is decided based on the granted authority shall be to reinforce the Company's working capital to finance the market launch of the Company's method EDOR®.

*A valid resolution on this item requires that the proposal is supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the meeting.*



**Other**

The Board's complete proposal for resolution and proxy forms will be available from the Company's registered office, Emotra AB, c/o AstraZeneca BioVentureHub, Pepparedsleden 1, SE-431 83 Mölndal, Sweden, as well as on the Company's web site ([www.emotra.se](http://www.emotra.se)) and can be sent on request to shareholders who provide their mailing address.

Shareholders who participate in the meeting have the right to request information as per Chap. 7, Section 32 of the Swedish Companies act (2005:551).

Göteborg, November 2020

**EMOTRA AB (publ)**

THE BOARD OF DIRECTORS

**For further information about Emotra, please contact:**

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

EMOTRA AB, AstraZeneca BioVentureHub, Pepparedsleden 1  
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)